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INTRODUCTION: 
Depression is an important global public health problem 
due to its relatively high lifetime prevalence and 
significant disability caused by it. It accounts for almost 
12% of the total years which were lived with disability 
worldwide
1
. The WHO defines depression as a 
pessimistic sense of inadequacy and a despondent lack 
of activity. It can be defined as a mental state which is 
characterized by feelings of sadness, loneliness, despair, 
low self-esteem, and self-reproach. The accompanying 
signs include psychomotor retardation or at times, 
withdrawal from interpersonal contact and vegetative 
symptoms such as anorexia and insomnia. Depression is 
associated with marked personal, social and economic 
morbidity affecting 9.5% of population worldwide 
2
. A 
recent American survey found the prevalence of current 
depression to be 9% and the rate of current major 
depression to be 3.4% 
3
. Over the past several decades, 
pharmacologic management of depressive disorders has 
evolved substantially. Despite the introduction of many 
new antidepressant medications and a continually 
advancing understanding of their individual strengths 
and weaknesses, selecting the best possible treatment 
ABSTRACT 
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and significant disability caused by it. The present study was conducted to compare improvement in functional outcome by 
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depression rating scale (HAM-D). The improvement in functional outcome was compared between the two groups by using 
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for each individual patient remains a significant 
challenge for general practitioners and psychiatrists. 
Response and remission are key goals in the 
management of depression.  Acceptability is also an 
important step towards achieving these goals, since 
patients require long-term (often life-long) 
pharmacotherapy (. First-line pharmacotherapy for 
depressive disorders typically chosen from among the 
―newer antidepressants‖— either a selective serotonin 
reuptake inhibitor (SSRI) or a serotonin-norepinephrine 
reuptake inhibitor (SNRI)
5
. Escitalopram, the S-
enantiomer of citalopram, is a selective serotonin 
reuptake inhibitor (SSRI) antidepressant that is the most 
selective of the SSRIs 
6
. The efficacy of escitalopram 
has been demonstrated in major depressive disorder 
(MDD) in both primary care and specialist settings
7-9
. 
Amisulpride is a substituted benzamide derivative 
structurally related to sulpiride. It belongs to the 
second-generation antipsychotic that preferably binds to 
dopamine D2/D3 receptors in limbic rather than striatal 
structures
10
. Amisulpride is indicated for the treatment 
of acute and chronic schizophrenia with prominent 
positive and/or negative symptoms due to a dose-
dependent blockade of dopamine receptors
10,11
. In 
addition to antipsychotic effects, preliminary reports 
suggest that Amisulpride may have antidepressant 
effects in dysthymia. Amisulpride has been shown to be 
as effective as comparator in clinical studies in patients 
with dysthymia and/or major depression 
12
. The 
presumed selectivity of amisulpride for D2 and D3 
dopamine receptors has led to the prevailing hypothesis 
that modulation of dopaminergic signaling is 
responsible for its antidepressant efficacy. Recent 
evidence suggests that primary-care providers do not 
decide on drug treatment or referral for depression on 
the basis of questionnaire scores alone, and that they 
consider practical wisdom and clinical judgment to be 
more important than objective assessments
13,14
. 
Assessment of function may, therefore, provide 
additional, important efficacy information over and 
above that provided by measuring response and 
remission. In this regard, emerging data show that 
escitalopram has an ability to improve functional 
outcomes in depression patients 
15, 16
. Based on the 
above observations, the present study was conducted to 
compare efficacy of Amisulpride and Escitalopram by 
HAM-D and improvement in functional outcomes by 
Sheehan‘s Disability Scale (SDS) among depression 
patients in a tertiary care teaching hospital in Nepal.  
MATERIAL AND METHODS: 
This study was conducted in the Department of 
Neuropsychiatry, Nepalgunj Medical College & 
Teaching Hospital, Nepalgunj, for a period of 1 year 
from January 2013 to December 2013. Institutional 
Ethics Committee approval and written informed 
consent from the patients or legal guardians were taken 
prior to the commencement of the study. Inclusion 
Criteria: (a) All drug naive patients attending the 
Neuropsychiatry OPD, of both sexes who were 
diagnosed as F 34.1, according to ICD 10 (World 
Health Organization, 2008). (b) Score ≥ 14 points on 
the Hamilton Depression Rating Scale (1980) on the 
first screening visit. Exclusion Criteria: (a) Use of 
psychoactive substances (b) any systemic illness (c) 
lactating and pregnant women (d) known case of 
psychiatric illness as described by ICD 10 (World 
Health Organization, 2008), (e) History of Drug 
reaction. 
Study Design: The study was an open label study 
conducted from January 2013 to December 2013. A 
total of 117 patients diagnosed with depression were 
randomly divided in two groups: Group I (58 patients) 
receivedtabletAmisulpride50 mg/day orally and Group 
II (59 patients) were given tablet Escitalopram 10 
mg/day orally. Drug compliance was monitored 
rigorously, but no drug blood levels were monitored due 
to lack of any such facility locally. The patients were 
followed up at 4, 8 and 15 weeks. Adverse drug 
reactions were monitored at every follow up. 
Appropriate statistical tools using GraphPadInstat 3.0 
were used for analysis. p value < 0.05 was considered 
significant. 
RESULTS: 
Out of a total of 117 patients which were included in the 
study, 18 patients dropped out from the study due to 
varying reasons: 6 patients were lost to follow up, 6 
patients decided to withdraw from the study due to 
adverse drug reactions, 3 patients were lost due to lack 
of cost effectiveness, 2 patients requested therapy 
change and 1 patient was uncooperative. Overall, 99 
patients completed the study: 48 patients in Amisulpride 
group and 51 patients in Escitalopram group. The mean 
age of the patients in the study drug groups was 
46.84±1.10 years. The male: female percentage was 
41(41.41%) and 58(58.59%). In our study, 31(31.31%) 
patients were residing in urban areas and 68(68.69%) 
patients were residing in rural areas. A total of 
47(47.47%) patients were illiterate and 52(52.53%) 
patients were literate. 65(65.66%) patients were 
farmers, 23(23.23%) patients were employed and 
11(11.11%) belonged to others category (table 1&2).
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Table 1: Demographic Profile of study group 
(All the values are expressed in Mean ± SEM) 
Variables Total 
Age (Mean) 46.84± 1.10 
Sex (M:F) 41(41.41%): 58(58.59%) 
 Urban: Rural 31: 68 (31.31%, 68.69%) 
Illiterate: Literate 47:52 (47.47%, 52.53%) 
Occupation:  
Farming 65 (65.66%) 
Employed 23 (23.23%) 
Others 11 (11.11%) 
 
Table 2: Drop Outs 
Variables 
Amisulpride 
n=58 
Escitalopram 
n=59 
Total 
n=117 
Total  Drop Outs 10 08 18 
Reasons:  
Lost to follow up 03 03 06 
Un Cooperative 00 01 01 
Adverse drug reaction 03 03 06 
Requested therapy change 01 01 02 
Lack of cost effectiveness 03 00 03 
Total completed study 48 51 99 
 
The efficacy of the drugs was calculated by Hamilton 
depression rating scale (HAM-D) and improvement in 
functional outcomes was measured by Sheehan‘s 
Disability Scale(SDS). All values were expressed in 
Mean ± SEM. At the beginning of the study, the HAM-D 
Score in Amisulpride group was 16.92±0.35 and in the 
Escitalopram group was 17.09±0.39 respectively. There 
was no significant difference between the two groups at 
the start of study (p >0.05). Patients were followed up at 
4, 8 and 15 weeks. Progressive improvement was seen in 
both the groups over the study period (figure 1).  
 
 
Figure 1: Progressive change of HAM-D score over study period 
 
At the end of the study, the HAM-D score in 
Amisulpride group was 7.87±0.29 and in the 
Escitalopram group was 6.63±0.39 respectively. 
Intragroup comparison was done between baseline and 
15 weeks and highly significant improvement was seen 
in both groups (p<0.0001). At the end of study period 
intergroup comparison was made between the two 
groups which was insignificant (p>0.05) (table 3). At 
the beginning of study, the Sheehan‘s Disability Scale 
(SDS) in Amisulpride group was 20.35±0.31 and in 
Escitalopram group was 21.53±0.55 respectively. 
Intergroup comparison was insignificant (p>0.05). At 
the end of study, SDS score in Amisulpride group was 
11.08±0.60 and in Escitalopram group was 11.49±0.46 
respectively. Intragroup comparison was done between 
baseline and 15 weeks which was highly significant in 
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both the groups (p<0.0001). Intergroup comparison at 
the end of study was insignificant (p>0.05) (table 4). A 
total of 44 adverse drug reactions (ADRs) were seen 
during the study period. 25 ADRs were seen in patients 
in Amisulpride group and 19 ADRs were seen in 
Escitalopram group. Gastrointestinal disturbances were 
seen in 5 patients in Amisulpride group and 9 patients 
in Escitalopram group followed by Delayed orgasm in 5 
patients in Amisulpride group and 2 patients in 
Escitalopram group, Amenorrhoea in 4 patients in 
Amisulpride group, dryness of mouth in 03 patients in 
Amisulpride group and 02 patients in Escitalopram 
group, erectile dysfunction in 02 patients in 
Amisulpride group and 01 patient in Escitalopram 
group, agitation in 02 patients in both groups, giddiness, 
insomnia and weight gain in 1 patient in each group and 
lactation in 1 patient in Amisulpride group (table 5).
 
Table 3: Efficacy as per HAM-D 
(All the values are expressed in Mean ± SEM) 
Drug 0 weeks 15 weeks p- value 
Amisulpride 16.92± 0.35 7.87± 0.29 <0.0001 
Escitalopram 17.09± 0.39 6.63± 0.39 <0.0001 
p- value > 0.05 >0.05  
 
Table 4: Functional outcomes as per SDS 
(All the values are expressed in Mean ± SEM) 
Drug 0 weeks 15 weeks p- value 
Amisulpride 20.35± 0.31 11.08± 0.60 <0.0001 
Escitalopram 21.53± 0.55 11.49± 0.46 <0.0001 
p- value > 0.05 >0.05  
 
Table 5: Adverse Drug Reactions 
Variables 
Amisulpride 
-------------- 
n=48 
Escitalopram 
--------------- 
n=51 
Total patients with ADR  25(59%) 19(42.2%) 
Gastrointestinal disturbances 05 09 
Delayed orgasm 05 02 
Amenorrhea 04 00 
Dryness of Mouth 03 02 
Erectile Dysfunction 02 01 
Agitation 02 02 
Giddiness 01 01 
Insomnia 01 01 
Weight gain 01 01 
Lactation 01 00 
 
DISCUSSION: 
Depressive disorders lead to significant dysfunction, 
disability and poor quality of life in sufferers and pose a 
significant burden on the caregivers 
17, 18
. In the present 
study there was a higher prevalence of depression in 
females which was in accordance with previous studies 
by Sethi et al and Ramachandran et al depicting that 
women were more commonly suffering from 
depression
19, 20
. The greater prevalence of depression 
among women is not fully understood, although 
potential contributors include different responses to 
stressful life events, genetic predisposition and 
hormonal differences 
21
. The mean age group in our 
study was 46.84±1.10 years which was comparable with 
previous studies by Dutta et al and Grover et al where 
incidence of depression was seen predominantly in 30-
51 years age group 
22, 23
.  More depression patients were 
seen in rural areas as compared to urban areas in the 
present study. This was comparable with previous 
studies by Paritala et al, Giel et al and Gautam et al 
where rural back ground subjects were found to be 
somatising more than the urban subjects
24-26
. In our 
study more number of literates was suffering from 
depression which was comparable with previous study 
by Paritala et al and Barsky et al 
24, 27
. Farmers were the 
major sufferers of depression which was in accordance 
with previous studies by Roberts and Lee 
28
 which was, 
based on data from the Epidemiologic Catchment Area 
(ECA) Program, found ‗farming, fishing and forestry‘ 
to have the highest lifetime risk for major depression. 
Other studies have also shown increased suicide rates 
among farmers 
29, 30
. 
A comparative evaluation of Escitalopram and 
Amisulpride was done in depression patients by 
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measuring improvement in functional outcome using 
Sheehan‘s Disability Scale in this 15 week study. 
Escitalopram is an allosteric selective serotonin 
reuptake inhibitor (SSRI) with some indication of 
superior efficacy in the treatment of major depressive 
disorders. The results of our study revealed highly 
significant improvement in HAM-D in depressive 
patients over the study period. Intragroup comparison 
was made between baseline and 15 weeks in 
Escitalopram group, highly significant improvement 
was seen (p<0.0001). This was comparable with 
previous studies where efficacy of escitalopram has 
been proven 
8, 9, 31
. Amisulpride, a selective D2/D3 
receptor second generation antipsychotic is indicated 
for the treatment of acute and chronic schizophrenia 
32
. 
The presumed selectivity of Amisulpride for D2 and D3 
dopamine receptors has led to the prevailing hypothesis 
that modulation of dopaminergic signaling is 
responsible for its antidepressant efficacy. In the present 
study the antidepressant effect of Amisulpride was 
compared at baseline and at 15 weeks in depressive 
patients, highly significant improvement was observed 
(p<0.0001). This was comparable with previous studies 
by Ravizza L et al and Lecrubier Y  et al where 
antidepressant role of Amisulpride has been proven
33-34
. 
Amisulpride has some selectivity for presynaptic 
dopamine autoreceptors, and exhibits limbic versus 
striatal selectivity, particularly at low doses, and it has 
been suggested that this might account for its 
therapeutic profile 
35
. 
The improvement in functional impairment was 
measured by SDS. In the present study highly 
significant improvement was seen in both Escitalopram 
and Amisulpride groups. Previous studies by Cipriani et 
al. and Wade et al, have also shown favorable outcomes 
in SDS for Escitalopram
36, 15
 and study by Smeraldi et 
al has shown improvement in SDS by Amisulpride, 
which is comparable to the present study. Proving that 
patients who take medications that are efficacious and 
acceptable have a better chance of achieving superior 
functional improvements compared to those who take 
agents that are less efficacious and/or not as well 
accepted
35
. At the end of the study period, intergroup 
comparison was made between Escitalopram group and 
Amisulpride group which revealed no significant 
difference (p<0.05), indicating both the drug were 
equally efficacious in improving depression and in 
improving functional outcome. 
Safety analysis was done for both the groups and 
adverse drug reactions were assessed at each follow up. 
Gastrointestinal disturbances were seen most commonly 
with both the groups and have been proven in earlier 
studies 
37, 38
. Endocrinological effects like Amenorrhoea 
and lactation were seen in Amisulpride group and have 
been seen in previous studies 
39
. Other side effects like 
insomnia, agitation and dryness of mouth were seen 
similarly in both groups and were comparable with 
previous studies 
40, 41
. 
Study Limitations: The study was an open label study. 
Both doctors and patients were aware of the treatments. 
Hence there could be chances of bias. Sample size was 
small and the patients were followed up for only 15 
weeks.  
CONCLUSION: 
Both Escitalopram and Amisulpride were highly 
effective in improving functional outcome in depression 
patients. But intergroup comparison revealed no 
significant difference between the two groups. A double 
blind study with larger sample size and longer duration 
of follow up can substantiate the findings of the present 
study. 
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